Wellington Management Group
AMLX icon

Wellington Management Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Wellington Management Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Sell
212,842
-28,710
-12% -$444K ﹤0.01% 1501
2026
Q1 		$3.36M Buy
241,552
+15,770
+7% +$222K ﹤0.01% 1464
2025
Q4 		$2.73M Sell
225,782
-10,415
-4% -$141K ﹤0.01% 1524
2025
Q3 		$3.21M Sell
236,197
-52,421
-18% -$493K ﹤0.01% 1530
2025
Q2 		$1.85M Sell
288,618
-2,064
-0.7% -$10K ﹤0.01% 1594
2025
Q1 		$1.03M Buy
290,682
+80,974
+39% +$288K ﹤0.01% 1704
2024
Q4 		$793K Buy
+209,708
New +$987K ﹤0.01% 1762
2024
Q2 		– Sell
-33,933
Closed -$96.4K – 1877
2024
Q1 		$96.4K Sell
33,933
-10,820
-24% -$142K ﹤0.01% 1885
2023
Q4 		$659K Buy
+44,753
New +$686K ﹤0.01% 1693
2023
Q3 		– Sell
-17,716
Closed -$382K – 1803
2023
Q2 		$382K Sell
17,716
-90,713
-84% -$2.45M ﹤0.01% 1717
2023
Q1 		$3.18M Buy
108,429
+40,524
+60% +$1.41M ﹤0.01% 1392
2022
Q4 		$2.51M Buy
+67,905
New +$2.41M ﹤0.01% 1457

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Wellington Management Group's AMLX Position: Q2 2026 in Review

Wellington Management Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 12% in Q2 2026, selling an estimated $444K and leaving 212,842 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1501.

Wellington Management Group first reported a position in AMLX in Q4 2022 and has held it in 12 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Wellington Management Group held 212,842 shares of Amylyx Pharmaceuticals worth $3.82M as of Q2 2026.
  • Wellington Management Group sold 28,710 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $444K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1501 holding.
  • Wellington Management Group first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.